Xiuli Wang
Beckman Research Institute
20 Papers
81 Citations
Xiuli Wang is an academic researcher from Beckman Research Institute. The author has contributed to research in topics: Chimeric antigen receptor & T cell. The author has an hindex of 6, co-authored 20 publications. Previous affiliations of Xiuli Wang include City of Hope National Medical Center.
Chat about Author
Papers
Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
Eugenia Zah,Eugenia Zah,Eunwoo Nam,Vinya Bhuvan,Uyen Tran,Brenda Y. Ji,Stanley B. Gosliner,Xiuli Wang,Christine E. Brown,Yvonne Y. Chen +9 more
TL;DR: It is demonstrated that BCMA/CS1 bispecific CAR-T cells exhibit superior CAR expression and function compared to T cells that co-express individual BCMA and CS1 CARs, and the vertically integrated optimization process can be used to develop robust cell-based therapy against novel disease targets.
Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting.
Domenico Viola,Ada Dona,Ada Dona,Enrico Caserta,Enrico Caserta,Estelle Troadec,Estelle Troadec,Francesca Besi,Francesca Besi,Tinisha McDonald,Lucy Ghoda,Emine Gulsen Gunes,Emine Gulsen Gunes,James F. Sanchez,Jihane Khalife,Jihane Khalife,Marianna Martella,Marianna Martella,Chatchada Karanes,Myo Htut,Xiuli Wang,Michael Rosenzweig,Arnab Chowdhury,Douglas W. Sborov,Rodney R. Miles,Paul J. Yazaki,Todd Ebner,Craig C. Hofmeister,Stephen J. Forman,Steven T. Rosen,Guido Marcucci,John E. Shively,Jonathan J Keats,Amrita Krishnan,Flavia Pichiorri,Flavia Pichiorri +35 more
TL;DR: It is reported that CD38+ NK cells may be an unexplored therapeutic target for priming the immune system of MM patients and maintain targetable unmutated surface CD38 expression on their MM cells, but retain effector cells with impaired cellular immune function.
75
Adult Patients with ALL Treated with CD62L+ T Naïve/Memory-Enriched T Cells Expressing a CD19-CAR Mediate Potent Antitumor Activity with a Low Toxicity Profile
Samer K. Khaled,Suzette Blanchard,Xiuli Wang,Jamie Wagner,Araceli Naranjo,Jennifer Simpson,Sandra H. Thomas,Julie R. Ostberg,Christine E. Brown,Stephen J. Forman +9 more
TL;DR: This phase I study used the activity constrained for toxicity (ACT) design, an extension of the toxicity equivalence range (TEQR) design of Blanchard and Longmate, that dose escalates based on lack of activity, while constraining the dose for toxicity.
12
Patent
Bi-specific targeted chimeric antigen receptor t cells
Xiuli Wang,Stephen J. Forman,Don J. Diamond +2 more
- 28 Mar 2016
TL;DR: T cells expressing a chimeric antigen receptor and a T cell receptor specific for CMV (bi-specific T cells) are described as a methods for using such cells in immunotherapy as mentioned in this paper.
10
A Mathematical Modeling Approach for Targeted Radionuclide and Chimeric Antigen Receptor T Cell Combination Therapy.
Vikram Adhikarla,Dennis Awuah,Alexander B Brummer,Enrico Caserta,Amrita Krishnan,Flavia Pichiorri,Megan Minnix,John E. Shively,Jeffrey Y.C. Wong,Xiuli Wang,Russell C. Rockne +10 more
TL;DR: In this article, the effects of dose, timing, and sequencing of targeted radionuclide therapy (TRT) and CAR-T cell-based therapies in a multiple myeloma setting were explored.
10